Economics of Innovation
Optimal innovation balances willingness and ability to pay with the benefits of future R&D. Our wide-ranging programme aims to promote innovation in health care, increase our understanding of its value, and encourage R&D. New models of innovation should streamline development, reduce costs, and speed patient benefit.
Price Comparisons of Identical Products in Japan, the United States and Europe
1 August 1981
The promotion of an environment in which the multinational research-based pharmaceutical industry can flourish has been and will continue to be reliant upon a well-informed and…
Economic Aspects of the Development of New Medicines
1 January 1981
A lecture, on the economics of developing new drugs, particularly in relation to whether this should be a national or private enterprise. I have chosen to…
Medicines: 50 Years of Progress 1930-1980
7 January 1980
The Office of Health Economics was invited to make a contribution to the celebration of the Golden Jubilee of the ABPI. This booklet is our response.…
Question of Balance: the Benefits and Risks of Pharmaceutical Innovation
1 May 1980
Since this monograph was completed, two new stories concerning the safety of medicines have been featured prominently in the British press. The first has been on…
Medicines for the year 2000
1 September 1979
A symposium held at the Royal College of Physicians, London in September 1978 by the Office of Health Economics. I do not want to trespass into…
Health Care Research Expenditure
1 June 1978
In the financial year 1976-77 over £220 million was spent on health care research in the United Kingdom. Taking account of recent expenditure growth and making…
Pharmaceutical Prices: A continental view
1 April 1978
It has not normally been OHE policy to reprint articles which have previously been published elsewhere. However, it seemed desirable to make an exception for this…
Brand Names in Prescribing
1 September 1976
To present a balanced view of the brand name/generic controversy and the associated field of bioavailability. Many have discussed these problems; scientists, politicians, industrialists, legislators, hospital…
Canberra Hypothesis: the Economics of the Prescription Medicine Market
1 July 1975
The Office of Health Economics delivered a paper to the Pharmaceutical Sciences Section of the Australian and New Zealand Association for the Advancement of Science at the Academy of Sciences in Canberra.